236 related articles for article (PubMed ID: 37377608)
1. Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
Nakhle J; Khattar K; Özkan T; Boughlita A; Abba Moussa D; Darlix A; Lorcy F; Rigau V; Bauchet L; Gerbal-Chaloin S; Daujat-Chavanieu M; Bellvert F; Turchi L; Virolle T; Hugnot JP; Buisine N; Galloni M; Dardalhon V; Rodriguez AM; Vignais ML
Cancer Res Commun; 2023 Jun; 3(6):1041-1056. PubMed ID: 37377608
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
[TBL] [Abstract][Full Text] [Related]
3. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
[TBL] [Abstract][Full Text] [Related]
4. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
[TBL] [Abstract][Full Text] [Related]
5. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
6. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M
Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906
[TBL] [Abstract][Full Text] [Related]
7. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
[No Abstract] [Full Text] [Related]
8. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
9. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
11. Pam
Megías J; Martínez A; San-Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Albert-Bellver D; Carratalá A; Gozalbo D; López-Ginés C; Gil ML; Cerdá-Nicolás M
Invest New Drugs; 2020 Apr; 38(2):299-310. PubMed ID: 31076963
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
[TBL] [Abstract][Full Text] [Related]
13. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Bi CL; Liu JF; Zhang MY; Lan S; Yang ZY; Fang JS
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33057597
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
17. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
18. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Riccitelli E; Giussani P; Di Vito C; Condomitti G; Tringali C; Caroli M; Galli R; Viani P; Riboni L
PLoS One; 2013; 8(6):e68229. PubMed ID: 23826381
[TBL] [Abstract][Full Text] [Related]
19. TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Morelli MB; Nabissi M; Amantini C; Maggi F; Ricci-Vitiani L; Pallini R; Santoni G
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499683
[TBL] [Abstract][Full Text] [Related]
20. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]